An anti‐EGFR mAb, cetuximab, which had shown to be efficacious in head and neck cancer 12, was able to decrease proliferation and to increase apoptosis in highly EGFR‐overexpressing human GBM xenografts 13. This evidence concerns the gene EGFR and head and neck cancer.